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Background: Research requires high quality ethical and governance scrutiny and approval. However, 
when research is conducted across different countries this can cause challenges delays due to the 
differing requirements of ethical boards.  There is no specific guidance for research which does not 
involve non-medicinal products (non-CTIMP).  
Aim:  
To compare the experience of researchers involved in collaborative European studies in relation to 
ethical and research governance procedures applied by research ethics for non-pharmaceutical 
palliative care studies including adult participants. 
To examine the experience of researchers in relation to variation in ethical procedures applied by 
research ethics committees for palliative care non-CTIMP studies in European countries? 
Design: An online survey analysed using descriptive statistics 
Setting/Participants: 18 principal investigators in 11 countries conducting one of three European 
funded studies funded through the FP7 Framework. 
Results: There was variation in practice including whether ethical approval was required. The time to 
gain full approvals differed with the UK having governance procedures that took the longest time.  
Written consent was not required in all countries nor were data safety monitoring committees for 
trials. There were additional differences in relation to other data management issues.  
Conclusions: Researchers need to take the differences in research approval procedures into account 
when planning studies. Future research is needed to establish Europe wide recommendations for 
policy and practice that dovetail ethical procedures and enhance transnational research 
collaborations. 
What is already known about the topic? 
 Variation in ethical review practice is recognised but mainly from the ethical committees 
perspective 
 Little evidence on the experience of gaining ethical approval for multi-site, transnational 
research in practice 
What this paper adds? 
 Variation continues to exist in ethical and research governance approval procedures across 
Europe 
 Interpretation of GDPR differs across Europe which has implications about how research is 
conducted. 
 Variation in practice was not related to the perceived vulnerability of patients in palliative 
care trials rather standard procedures applied in most countries 
Implications for practice, theory or policy 
 Researchers need to be aware of differences in research governance procedures when 
planning international research in particular time to gain full approval. 
 The differences in approval procedures need greater review  
 Future policy development is recommended to guide research ethical and governance 
procedures across Europe 
Key words: ethics, surveys and questionnaires, Europe, palliative care, clinical trial as topic, research 
governance 
Background 
To ensure that research is ethically robust, ethical and governance review is required to carefully 
examine projects before approval. These procedures can be organised at national or local levels but 
little is known about the varying degrees of practice both within and between countries. Ethical 
examination requires assessment of the potential risk a research study may have. When research 
involves potentially vulnerable participants such as in palliative care, this scrutiny becomes even 
more important. 
For researchers to conduct international collaborative research, there needs to be an appreciation of 
ethical and governance requirements in the countries involved. International variation in ethical 
review has been noted in the experiences of ethical review boards1-6 and the researchers’ 
perspective7. Whilst the Declaration of Helsinki promotes a set of ethical standards8, in practice 
committees, sometimes even on a regional level, apply their own interpretation of these criteria in 
their approval processes. This can result in disparity with some criteria being more stringently 
applied than others particularly when the research participants are receiving palliative care and 
perceived as vulnerable 9, 10,11   
Ethics committees assess also how researchers approach and access data about potential 
participants. The introduction of the European wide General Data Protection Regulations12 will also 
impact on these processes. Data restrictions may include access to medical records leaving 
identification of potential research participants to clinical staff who may not prioritise research. At 
the same time, gaining Good Clinical Practice  certification or its equivalent is a mandatory 
requirement in some countries enabling more robust research practice.   
Aim 
To describe and address differences in ethical and research governance procedures applied by 
research ethics committees for non-pharmaceutical palliative care collaborative European studies 
including adult participants. 
Methods 
An online descriptive study was conducted to describe and compare the ethical and review 
governance procedures across three European studies (7th Framework Programme)  (Box 1) with 
data collected in 11 different countries. Study designs included a cluster randomised controlled trial 
in oncological hospital settings (ACTION), a cluster randomised controlled trial in nursing and care 
homes (PACE), and  organisational studies in community settings (InSup-C). For each study, a single 
research protocol was used across all partner nations to obtain ethical approval.  
Design and data collection  
An online survey was used to capture the experiences. The survey was developed through 
consultation between the research teams and piloted on two study-naïve researchers. Ethical 
approval was obtained from Lancaster University (FHMREC14107). A link to the online survey was 
sent to 18 principal investigators  in 11 countries conducting one of the three studies (responses 
stored on password protected computers). The principal investigator either completed the survey or 
delegated it to another member of their research team. The survey comprised of 20 tick box and 
free text domains and a narrative ‘general comments’ section. It covered questions about local 
ethical and governance approval procedures including: necessity for ethical approval, research 
governance processes, timeframes, additional approvals, access to patient records, consent, and 
Good Clinical Practice requirements. Data were analysed using descriptive statistics and content 
analysis. 
Results 
Seventeen investigators responded (no response from Poland). Ethical approval was not required in 
Denmark (ACTION) and the Netherlands (InSup-C) as the studies were not seen as trials in the same 
way as a drug study. In Germany (InSup-C) ethical approval was only required for patient 
participation rather than family carer or health care staff. 
Eight of the 17 investigators were required to go through formal ethical review in addition to other 
approval processes. Only the UK required this on PACE. Only investigators in the UK were invited to 
attend the ethics committee meeting. Changes to the protocol were required post-ethical review in 
Belgium (InSup-C), Finland (PACE), Italy (ACTION and PACE) and the UK (PACE). The time taken to 
gain ethical approval varied as did additional research governance requirements (table 1). The PACE 
study gained the speediest approval and ACTION the longest. Overall, the UK had the slowest 
approval processes.  
Verbal consent was seen as sufficient for interview studies in some countries such as Germany and 
the Netherlands in InSup-C. Where ethical approval was not required for a study (e.g. ACTION in 
Denmark) or certain participants such as carers or staff in InSup-C in Germany and the Netherlands, 
the teams chose to implement high levels of ethical practice including gaining consent.  
A formal data safety monitoring committee was only mandatory in the UK (ACTION) which, in turn, 
led to this being required in all participating nations. However, in the Netherlands, it was stated that 
as ‘…our study was classified as low risk, we don’t need a whole data monitoring committee, but just 
a person who monitors our data collection process’. Good Clinical Practice  certification was needed 
in only four countries (Table 2). In Denmark where no ethical approval was required, additional 
approval was gained to screen medical records from the Danish Health and Medicines Authority.  
Researchers were permitted to screen for potential participants by reviewing clinical notes in four 
sites: Finland (PACE), Hungary (InSup-C), Italy (ACTION only) and Slovenia (ACTION). Research nurses 
performed this function in the UK (ACTION and InSup-C), Denmark (ACTION), Finland (PACE), Italy 
(PACE), Switzerland (PACE), and Slovenia (ACTION). The UK was alone in needing public and patient 
consultation (PPI) in research design to gain approval.  
Discussion/Conclusion 
The value of collaborative transnational research programmes are paramount. This study aimed at 
providing, for the first time, palliative care researchers with a comparative view of practice in ethical 
and governance approval processes in 11 European Countries. The main findings were (1) 
considerable diversity in ethical review practice between the participating countries exists; (2) the 
study settings and design may influence the speed of approval decisions; and (3) overall, the UK had 
the longest ethical and research governance approval procedures.  
As with all surveys, the responses given may not be a true representation of what happened in 
practice. There was some missing data, which may have skewed the results. However, nearly all 
responses were returned whilst the studies were ongoing, hence lapses in memory were likely to be 
minimal. Although members of the research team completed the survey, ultimately the authors 
were in essence describing their own experiences, which could cause some bias. 
The study corroborates and expands on previous findings reported for both observational5, 6, 13 and 
interventional studies7 in other research fields or non-trial research about palliative care2 . 
Differences still exist in ethical and research governance approval processes across Europe, 
especially in relation to how long studies take to be approved and what ethical committees classify 
as research, which need their approval. These results can help to inform researchers planning 
international studies by focusing attention on the variability of ethics and governance procedures for 
particular research designs, processes for screening potential participants, the involvement of the 
public in establishing research priorities and developing studies, and data management. Moreover, 
our results may help to increase attention to the need for agreed standards for approval procedures 
for non-pharmaceutical European studies, at least through training of ethical committees, as is 
happening in pharmaceutical studies.  
Ideally, such an agreement should also include different standards for observational and 
interventional designs. The two randomised controlled trials, PACE and ACTION, underwent the 
shortest and the longest approval procedure respectively. The longer time required for the approval 
of the ACTION trial may be longer because the study involved patients receiving an intervention 
rather than training staff to deliver an intervention, such as in PACE, and the patient group seen as 
more vulnerable. 
 
Finally, considering the UK was the first Country to lead European Union FP5 and FP6 projects14, the 
longest approval in UK is somewhat concerning. Indeed, prolonged ethical approval processes, 
especially when they concern the research lead country, increase research costs, delay recruitment, 
and can slow collaborative endeavour. On the other hand, high levels of scrutiny are needed to 
promote ethically conducted research, especially when research involves vulnerable subjects. A 
balance between the ethical need to reduce the length of approving procedures, in order to make 
research results promptly available to the public, and the need for a careful ethical examination 
should be achieved.  
Future research is therefore required in all of these areas to establish Europe wide 
recommendations for policy and practice that dovetail ethical procedures and enhance transnational 
research collaborations. Indeed, even acknowledging that it would be difficult to reach an 
international standardized approach due to different national legal framework concerning human 
research6, any effort to obtain this goal is needed.  The differences in ethical review is remarkable 
given all countries want researchers to adhere to the declaration of Helsinki, which states in 
guideline 1 that it applies to (all) medical research involving human subjects, including research on 
identifiable human material and data (WMA, 2013). In reality however, countries are trying to find 
ways to get to a risk-adaptive governance structure for the ethical review of research. Our results 
point to the necessity to harmonize the ethical review of this kind of low risk research across Europe. 
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